NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,164,905 | +6.8% | 1,955,356 | +3.1% | 0.00% | – |
| Q2 2023 | $1,090,564 | -55.9% | 1,895,974 | -46.1% | 0.00% | – |
| Q1 2023 | $2,472,855 | +31676.6% | 3,518,076 | +2.2% | 0.00% | -100.0% |
| Q4 2022 | $7,782 | -99.9% | 3,443,711 | +3.5% | 0.00% | -50.0% |
| Q3 2022 | $10,643,000 | -13.9% | 3,325,990 | +2.2% | 0.00% | 0.0% |
| Q2 2022 | $12,365,000 | -6.5% | 3,253,963 | +32.6% | 0.00% | 0.0% |
| Q1 2022 | $13,224,000 | -58.5% | 2,453,464 | +4.1% | 0.00% | -50.0% |
| Q4 2021 | $31,851,000 | -24.9% | 2,357,653 | -0.1% | 0.00% | -33.3% |
| Q3 2021 | $42,400,000 | +3.4% | 2,360,819 | -1.2% | 0.01% | 0.0% |
| Q2 2021 | $40,997,000 | -11.9% | 2,389,130 | +2.7% | 0.01% | -14.3% |
| Q1 2021 | $46,534,000 | +19.8% | 2,326,729 | +1.8% | 0.01% | 0.0% |
| Q4 2020 | $38,858,000 | +12.4% | 2,285,776 | +9.7% | 0.01% | 0.0% |
| Q3 2020 | $34,579,000 | -30.8% | 2,084,334 | -3.4% | 0.01% | -36.4% |
| Q2 2020 | $49,982,000 | +32.6% | 2,158,132 | +2.2% | 0.01% | +10.0% |
| Q1 2020 | $37,684,000 | -57.2% | 2,111,172 | -48.2% | 0.01% | +11.1% |
| Q4 2019 | $88,050,000 | +72.0% | 4,079,292 | +44.9% | 0.01% | -25.0% |
| Q3 2019 | $51,198,000 | -47.0% | 2,814,872 | +3.4% | 0.01% | -47.8% |
| Q2 2019 | $96,680,000 | +20.2% | 2,721,513 | +13.5% | 0.02% | +9.5% |
| Q1 2019 | $80,433,000 | -45.1% | 2,398,081 | -46.3% | 0.02% | -8.7% |
| Q4 2018 | $146,618,000 | +8.1% | 4,468,392 | +100.5% | 0.02% | -39.5% |
| Q3 2018 | $135,646,000 | +42.9% | 2,229,038 | +14.5% | 0.04% | +31.0% |
| Q2 2018 | $94,897,000 | -56.2% | 1,947,262 | -4.7% | 0.03% | -59.2% |
| Q1 2018 | $216,685,000 | +150.9% | 2,042,359 | +41.2% | 0.07% | +144.8% |
| Q4 2017 | $86,353,000 | +151.3% | 1,445,971 | +1.0% | 0.03% | +123.1% |
| Q3 2017 | $34,368,000 | +27.4% | 1,432,013 | +3.7% | 0.01% | +18.2% |
| Q2 2017 | $26,985,000 | -14.2% | 1,380,357 | +3.0% | 0.01% | -15.4% |
| Q1 2017 | $31,452,000 | +115.6% | 1,340,104 | +12.7% | 0.01% | +85.7% |
| Q4 2016 | $14,585,000 | -15.4% | 1,188,735 | +18.4% | 0.01% | -22.2% |
| Q3 2016 | $17,247,000 | +22.3% | 1,003,951 | +1.3% | 0.01% | +12.5% |
| Q2 2016 | $14,099,000 | +4.7% | 990,835 | +1.1% | 0.01% | +14.3% |
| Q1 2016 | $13,472,000 | -11.9% | 979,790 | +7.9% | 0.01% | -22.2% |
| Q4 2015 | $15,294,000 | +60.0% | 907,683 | +4.1% | 0.01% | +50.0% |
| Q3 2015 | $9,557,000 | -9.3% | 872,030 | +3.6% | 0.01% | 0.0% |
| Q2 2015 | $10,532,000 | +17.6% | 841,915 | +3.4% | 0.01% | +20.0% |
| Q1 2015 | $8,956,000 | -22.8% | 814,258 | +8.8% | 0.01% | -28.6% |
| Q4 2014 | $11,598,000 | +30.5% | 748,321 | +1.6% | 0.01% | +16.7% |
| Q3 2014 | $8,886,000 | -4.8% | 736,250 | +1.2% | 0.01% | 0.0% |
| Q2 2014 | $9,330,000 | +10.1% | 727,825 | +4.1% | 0.01% | 0.0% |
| Q1 2014 | $8,476,000 | +29.5% | 699,399 | +21.3% | 0.01% | +20.0% |
| Q4 2013 | $6,544,000 | +20.9% | 576,629 | +11.3% | 0.01% | +25.0% |
| Q3 2013 | $5,414,000 | -6.7% | 518,093 | +3.1% | 0.00% | -20.0% |
| Q2 2013 | $5,804,000 | – | 502,513 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |